Valneva to test vaccine prototype in Japan
When any pandemic happens, Valneva researchers can determine the specific virus strain causing the pandemic and quickly produce and supply the new vaccine.
The prototype vaccine was created with a model virus from Valneva's EB66 line, which was made in collaboration with GlaxoSmithKline and is confirmed for safety and immunogenicity in human subjects. This development was made in a new, state-of-the-art facility in Kumamoto that can create 80 million doses of a vaccine for over 40 million people in just six months.
“This approval constitutes another major achievement and it will provide potential revenue stream for our EB66 platform,” Valneva's CEO Thomas Lingelbach and Chief Business Officer Franck Grimaud said.
Valneva now has over 35 license agreements for use of the EB66 line with several of the largest pharmaceutical companies in the world.